Ixed (Human Coagulation Factor Ix)

Human Coagulation Factor IX supplies the missing clotting factor in hemophilia B. Once administered intravenously, it binds to activated Factor VIII on phospholipid surfaces and catalyzes the conversion of Factor X to Xa, re‑establishing the intrinsic pathway of coagulation and enabling fibrin clot formation.

The dose of Ixed is individualized by the prescribing clinician based on the patient’s baseline Factor IX activity, the severity of bleeding, body weight, and the desired target level for a specific clinical situation. Dosing regimens are therefore set by the healthcare professional.

Safety data for Ixed in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Ixed, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Ixed is a recombinant Human Coagulation Factor IX presented as an injectable solution, similar in function to other recombinant or plasma‑derived factor IX concentrates. Differences may include manufacturing process, specific excipients, storage requirements, and regulatory approvals, which can influence immunogenicity, inhibitor risk and logistical handling.

Ixed must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use, and any unused portion should be discarded according to the supplier’s stability guidelines.

Ixed is administered by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and volume are determined by the prescriber based on the patient’s weight, target Factor IX level, and clinical context. Monitoring of Factor IX activity is recommended after administration.

Serious risks include the development of neutralizing inhibitors against Factor IX, severe allergic or anaphylactic reactions, and thrombotic events such as deep‑vein thrombosis. Patients should be observed for signs of hypersensitivity, unexpected clot formation, or loss of efficacy due to inhibitor formation.

Ixed is contraindicated in individuals with known hypersensitivity to Human Coagulation Factor IX or any of its excipients. Caution is also advised for patients with a history of thromboembolic disease, and it should be avoided in those who have previously developed high‑titer inhibitors to Factor IX.